Epstein-Barr virus: Silent companion or causative agent of chronic liver disease?

World Journal of Gastroenterology

Volumn 16, Issue 33, 2010, Pages 4130-4134

  Petrova, Mihaela ^a   Kamburov, Victor ^b  

^a Ministry of Interior   (Bulgaria)

^b Multiprofile Hospital for Active Treatment National Cardiology Hospital   (Bulgaria)

Author keywords

Chronic active epstein barr virus; Chronic hepatitis; Epstein barr virus; Infectious mononucleosis; Liver disease; Post transplant lymphoproliferative disorder

Indexed keywords

ACUTE HEPATITIS; CARCINOGENESIS; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; LIVER CANCER; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVER TUMOR; LYMPHOPROLIFERATIVE DISEASE; MEDICAL SPECIALIST; NONHUMAN; PATHOGENESIS; PRIMARY INFECTION; REVIEW; SEROLOGY; VIRUS GENOME; VIRUS LATENCY; VIRUS REACTIVATION;

EID: 77956640038     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i33.4130     Document Type: Review

References (59)

1. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481-492
2. Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol 2005; 6: 873-879
3. Maurmann S, Fricke L, Wagner HJ, Schlenke P, Hennig H, Steinhoff J, Jabs WJ. Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers. J Clin Microbiol 2003; 41: 5419-5428
4. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, eds. Fields virology. 4th ed, Vol 2. Philadelphia: Lippincott Williams & Wilkins, 2001: 2575-2627
5. Babel N, Schwarzmann F, Prang N, Jaeger M, Wolf H, Kern F, Volk HD, Reinke P. Association between Epstein-Barr virus infection and late acute transplant rejection in long-term transplant patients. Transplantation 2001; 72: 736-739
6. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virusassociated post-transplantation lymphoproliferative disease. Br J Haematol 1995; 89: 98-103
7. Gleeson M, Pyne DB, Austin JP, Lynn Francis J, Clancy RL, McDonald WA, Fricker PA. Epstein-Barr virus reactivation and upper-respiratory illness in elite swimmers. Med Sci Sports Exerc 2002; 34: 411-417
8. Kieff E. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology. 3rd ed, Vol. 2. Philadelphia: Lippincott-Raven, 1996: 2343-2396
9. Kerr BM, Lear AL, Rowe M, Croom-Carter D, Young LS, Rookes SM, Gallimore PH, Rickinson AB. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology 1992; 187: 189-201
10. Crum NF. Epstein Barr virus hepatitis: case series and review. South Med J 2006; 99: 544-547
11. Cocuz ME, Idomir ME, Ticǎu OC. [Clinical and biological aspects of liver damage in infectious mononucleosis] Bacteriol Virusol Parazitol Epidemiol 2003; 48: 177-181
12. Hinedi TB, Koff RS. Cholestatic hepatitis induced by Epstein-Barr virus infection in an adult. Dig Dis Sci 2003; 48: 539-541
13. Kimura H, Nagasaka T, Hoshino Y, Hayashi N, Tanaka N, Xu JL, Kuzushima K, Morishima T. Severe hepatitis caused by Epstein-Barr virus without infection of hepatocytes. Hum Pathol 2001; 32: 757-762
14. Edoute Y, Baruch Y, Lachter J, Furman E, Bassan L, Assy N. Severe cholestatic jaundice induced by Epstein-Barr virus infection in the elderly. J Gastroenterol Hepatol 1998; 13: 821-824
15. Papatheodoridis GV, Delladetsima JK, Kavallierou L, Kapranos N, Tassopoulos NC. Fulminant hepatitis due to Epstein-Barr virus infection. J Hepatol 1995; 23: 348-350
16. Markin RS, Linder J, Zuerlein K, Mroczek E, Grierson HL, Brichacek B, Purtilo DT. Hepatitis in fatal infectious mononucleosis. Gastroenterology 1987; 93: 1210-1217
17. Feranchak AP, Tyson RW, Narkewicz MR, Karrer FM, Sokol RJ. Fulminant Epstein-Barr viral hepatitis: orthotopic liver transplantation and review of the literature. Liver Transpl Surg 1998; 4: 469-476
18. Straus SE. The chronic mononucleosis syndrome. J Infect Dis 1988; 157: 405-412
19. Shibuya A, Tsuchihashi T, Watanabe M, Nakazawa T, Takeuchi A, Sakurai K, Mitomi H, Saigenji K. Severe chronic active Epstein-Barr virus infection associated with multiple necrotic lesions in the liver. Hepatol Res 2003; 25: 447-454
20. Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, Sabat R, Babel N, Jones JF, Webster-Cyriaque J, Gee AP, Brenner MK, Heslop HE, Rooney CM. Autologous Epstein- Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002; 100: 4059-4066
21. Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES. Epstein- Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol 2009; 20: 1472-1482
22. Jaffe ES, Wilson WH. Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications. Cancer Surv 1997; 30: 233-248
23. Vento S, Cainelli F. Is there a role for viruses in triggering autoimmune hepatitis? Autoimmun Rev 2004; 3: 61-69
24. Chiba T, Goto S, Yokosuka O, Imazeki F, Tanaka M, Fukai K, Takahashi Y, Tsujimura H, Saisho H. Fatal chronic active Epstein-Barr virus infection mimicking autoimmune hepatitis. Eur J Gastroenterol Hepatol 2004; 16: 225-228
25. Nobili V, Comparcola D, Sartorelli MR, Devito R, Marcellini M. Autoimmune hepatitis type 1 after Epstein-Barr virus infection. Pediatr Infect Dis J 2003; 22: 387
26. Vento S, Guella L, Mirandola F, Cainelli F, Di Perri G, Solbiati M, Ferraro T, Concia E. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet 1995; 346: 608-609
27. Kojima K, Nagayama R, Hirama S, Maeda T, Takikawa H, Miyake K, Yamanaka M, Shiga J. Epstein-Barr virus infection resembling autoimmune hepatitis with lactate dehydrogenase and alkaline phosphatase anomaly. J Gastroenterol 1999; 34: 706-712
28. Aceti A, Mura MS, Babudieri S, Bacciu SA. A young woman with hepatitis after a sore throat. Lancet 1995; 346: 1603
29. Biest S, Schubert TT. Chronic Epstein-Barr virus infection: a cause of granulomatous hepatitis? J Clin Gastroenterol 1989; 11: 343-346
30. Kikuchi K, Miyakawa H, Abe K, Fujikawa H, Horiuchi T, Nagai K, Kako M. Vanishing bile duct syndrome associated with chronic EBV infection. Dig Dis Sci 2000; 45: 160-165
31. Petrova M, Kamburov V, Nikolovska D, Kosseva O, Nikolova M, Krastev Z. Epstein-Barr virus: is there any contribution to chronic hepatitis B and C? Liver Int 2010; 30: 488-489
32. Jabs WJ, Wagner HJ, Schlenke P, Kirchner H. The primary and memory immune response to Epstein-Barr virus infection in vitro is characterized by a divergent production of IL- 1beta/IL-6 and IL-10. Scand J Immunol 2000; 52: 304-308
33. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL, Cabrera R, Liu C, Davis GL. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003; 38: 859-868
34. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-829
35. Santolamazza M, Marinelli RM, Bacosi M, D'Innocenzo S, Miglioresi L, Patrizi F, Delle Monache M, Ricci GL. What kind of hepatitis? J Int Med Res 2001; 29: 441-444
36. Sugawara Y, Makuuchi M, Kato N, Shimotohno K, Takada K. Enhancement of hepatitis C virus replication by Epstein-Barr virus-encoded nuclear antigen 1. EMBO J 1999; 18: 5755-5760
37. Bertolini L, Iacovacci S, Bosman C, Carloni G, Monaco V, Bangrazi C, Serafino A, Gualandi G, Prantera G, Fruscalzo A. Low cell dosage of lymphoblastoid human cell lines EBV(+) is associated to chronic hepatitis in a minority of inoculated Nu/Nu mice. J Med Virol 2002; 66: 70-81
38. Tugizov SM, Berline JW, Palefsky JM. Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med 2003; 9: 307-314
39. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997; 3: 409-413
40. Küsters S, Gantner F, Künstle G, Tiegs G. Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 1996; 111: 462-471
41. Bradham CA, Plümpe J, Manns MP, Brenner DA, Trautwein C. Mechanisms of hepatic toxicity. I. TNF-Induced liver injury. Am J Physiol 1998; 275: G387-G392
42. Mehal WZ, Juedes AE, Crispe IN. Selective retention of activated CD8+ T cells by the normal liver. J Immunol 1999; 163: 3202-3210
43. Drebber U, Kasper HU, Krupacz J, Haferkamp K, Kern MA, Steffen HM, Quasdorff M, Zur Hausen A, Odenthal M, Dienes HP. The role of Epstein-Barr virus in acute and chronic hepatitis. J Hepatol 2006; 44: 879-885
44. Petrova M, Muhtarova M, Nikolova M, Magaev S, Taskov H, Nikolovska D, Krastev Z. Chronic Epstein-Barr virus-related hepatitis in immunocompetent patients. World J Gastroenterol 2006; 12: 5711-5716
45. van Baarle D, Tsegaye A, Miedema F, Akbar A. Significance of senescence for virus-specific memory T cell responses: rapid ageing during chronic stimulation of the immune system. Immunol Lett 2005; 97: 19-29
46. Dunne PJ, Faint JM, Gudgeon NH, Fletcher JM, Plunkett FJ, Soares MV, Hislop AD, Annels NE, Rickinson AB, Salmon M, Akbar AN. Epstein-Barr virus-specific CD8(+) T cells that reexpress CD45RA are apoptosis-resistant memory cells that retain replicative potential. Blood 2002; 100: 933-940
47. Wills MR, Okecha G, Weekes MP, Gandhi MK, Sissons PJ, Carmichael AJ. Identification of naive or antigen-experienced human CD8(+) T cells by expression of costimulation and chemokine receptors: analysis of the human cytomegalovirus- specific CD8(+) T cell response. J Immunol 2002; 168: 5455-5464
48. Randhawa PS, Markin RS, Starzl TE, Demetris AJ. Epstein- Barr virus-associated syndromes in immunosuppressed liver transplant recipients. Clinical profile and recognition on routine allograft biopsy. Am J Surg Pathol 1990; 14: 538-547
49. Holmes RD, Sokol RJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant 2002; 6: 456-464
50. McDiarmid SV. Management of the pediatric liver transplant patient. Liver Transpl 2001; 7: S77-S86
51. Smets F, Sokal EM. Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management. Pediatr Transplant 2002; 6: 280-287
52. D'Antiga L, Del Rizzo M, Mengoli C, Cillo U, Guariso G, Zancan L. Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD. Liver Transpl 2007; 13: 343-348
53. Thorley-Lawson DA, Gross A. Persistence of the Epstein- Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350: 1328-1337
54. Sugawara Y, Makuuchi M, Takada K. Detection of Epstein- Barr virus DNA in hepatocellular carcinoma tissues from hepatitis C-positive patients. Scand J Gastroenterol 2000; 35: 981-984
55. Sugawara Y, Mizugaki Y, Uchida T, Torii T, Imai S, Makuuchi M, Takada K. Detection of Epstein-Barr virus (EBV) in hepatocellular carcinoma tissue: a novel EBV latency characterized by the absence of EBV-encoded small RNA expression. Virology 1999; 256: 196-202
56. Li W, Wu BA, Zeng YM, Chen GC, Li XX, Chen JT, Guo YW, Li MH, Zeng Y. Epstein-Barr virus in hepatocellular carcinogenesis. World J Gastroenterol 2004; 10: 3409-3413
57. Akhter S, Liu H, Prabhu R, DeLucca C, Bastian F, Garry RF, Schwartz M, Thung SN, Dash S. Epstein-Barr virus and human hepatocellular carcinoma. Cancer Lett 2003; 192: 49-57
58. zur Hausen A, van Beek J, Bloemena E, ten Kate FJ, Meijer CJ, van den Brule AJ. No role for Epstein-Barr virus in Dutch hepatocellular carcinoma: a study at the DNA, RNA and protein levels. J Gen Virol 2003; 84: 1863-1869
59. Chen H, Smith P, Ambinder RF, Hayward SD. Expression of Epstein-Barr virus BamHI-A rightward transcripts in latently infected B cells from peripheral blood. Blood 1999; 93: 3026-3032